BioWorld Asia

Sep. 9, 2009

Summit Sells Dextra Lab Unit, Now Has Funds to Stay Afloat

LONDON - Summit Corp. plc completed the life-saving divestment of its services businesses, selling its Dextra Laboratories subsidiary to New Zealand Pharmaceuticals for £950,000 (US$1.6 million). (BioWorld International) Read More

Robust GM Crop Pipeline Could Disrupt Trade, Says EC Report

2 Broad New HIV Antibodies Found, and More are Possible

LEO Buyout Gels for Peplin: $288M, Plus Phase III Loan

Kinaris Targeting Myosins with Allosteric Inhibitors

Senexis Passes Milestone and Triggers £2.9M for Clinic Pathway

Would-be Biogen Buyer's Path Clear, Elan in Tysabri Trouble

Irish Pharma Entrepreneur Puts Wealth into Medical Research

Tioga Pauses for Japanese Deal Ahead of Asimadoline Phase III

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 12, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...